New schizophrenia drug passes early safety check
NCT ID NCT05406440
First seen Apr 30, 2026 · Last updated May 15, 2026 · Updated 4 times
Summary
This early-stage study tested a new drug called MK-8189 (elpipodect) in 53 adults with schizophrenia or schizoaffective disorder. The main goal was to see if the drug is safe and tolerable when given in increasing doses. Participants were stable on their current treatment and in a non-acute phase of illness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
California Clinical Trials Medical Group managed by PAREXEL ( Site 0002)
Glendale, California, 91206, United States
-
Collaborative Neuroscience Research, LLC ( Site 0004)
Garden Grove, California, 92845, United States
-
Hassman Research Institute Marlton Site ( Site 0003)
Marlton, New Jersey, 08053, United States
Conditions
Explore the condition pages connected to this study.